GF Fund Management’s Pacific Biosciences PACB Stock Holding History

GF Fund Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7K	Sell	6,391 -314	-5%	-$457	﹤0.01%	532
2026 Q1	$8.85K	Buy	6,705 +773	+13%	+$1.38K	﹤0.01%	569
2025 Q4	$11.1K	Sell	5,932 -530	-8%	-$1.02K	﹤0.01%	565
2025 Q3	$8.27K	Sell	6,462 -329	-5%	-$446	﹤0.01%	570
2025 Q2	$8.42K	Hold	6,791	–	–	﹤0.01%	585
2025 Q1	$8.01K	Buy	6,791 +1,041	+18%	+$1.6K	﹤0.01%	587
2024 Q4	$10.5K	Buy	+5,750	New	+$11.2K	﹤0.01%	540

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GF Fund Management's PACB Position: Q2 2026 in Review

GF Fund Management reduced its Pacific Biosciences (PACB) stake by 4.7% in Q2 2026, selling an estimated $457 and leaving 6,391 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

GF Fund Management first reported a position in PACB in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.1K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

GF Fund Management held 6,391 shares of Pacific Biosciences worth $10.7K as of Q2 2026.
GF Fund Management sold 314 Pacific Biosciences shares in Q2 2026, an estimated $457.
Pacific Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #532 holding.
GF Fund Management first reported a position in Pacific Biosciences in Q4 2024 and has held it in 7 quarters since.
GF Fund Management's Pacific Biosciences position peaked at $11.1K in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.